Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.

Nature communications - 11 Mar 2020

Rendo Veronica, Stoimenov Ivaylo, Mateus André, Sjöberg Elin, Svensson Richard, Gustavsson Anna-Lena, Johansson Lars, Ng Adrian, OʼBrien Casey, Giannakis Marios, Artursson Per, Nygren Peter, Cheong Ian, Sjöblom Tobias

Abstract excerpt

Cancer chemotherapy targeting frequent loss of heterozygosity events is an attractive concept, since tumor cells may lack enzymatic activities present in normal constitutional cells. To find exploitable targets, we map prevalent genetic polymorphisms to protein structures and identify 45 nsSNVs (non-synonymous small nucleotide variations) near the catalytic sites of 17 enzymes frequently lost in cancer. For proof...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arylamine N-Acetyltransferase
Share to Bystander Effect

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HCT116 Cells

Share to Isoenzymes

Share to Loss of Heterozygosity

Share to Mice, Nude

Share to Small Molecule Libraries

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32161261
DOI: 10.1038/s41467-020-15111-4
PMCID: PMC7066191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.PMID 32161261Read ↗

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer.Semantic proximity Read ↗

Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity.Semantic proximity Read ↗

Loss of CYP2D6 sensitizes hepatocellular carcinomas and neuroblastomas to talazoparibSemantic proximity Read ↗

N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions.Semantic proximity Read ↗

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib.Semantic proximity Read ↗

Selective killing of cancer cells based on loss of heterozygosity and normal variation in the human genome: a new paradigm for anticancer drug therapy.Semantic proximity Read ↗

Mining cancer genomes for change-of-metabolic-function mutations.Semantic proximity Read ↗

Desperately seeking genotype-selective anticancer agents.Semantic proximity Read ↗

Prediction of individualized therapeutic vulnerabilities in cancer from genomic profilesSemantic proximity Read ↗

Screening and characterizing human NAT2 variants.Semantic proximity Read ↗

Human acetyl CoA:arylamine N-acetyltransferase variants generated by random mutagenesis.Semantic proximity Read ↗

Fine-tuning chemical genetics to identify physiologic drug targets.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.